new fda regulations for semaglutide FDA's Removal of and the Evolving Tirzepatide Decisions: What Compounders Need to Know FDA ends semaglutide shortage, closing

For labs comparing protocols, a simple matrix often helps: Need lower procedural complexity: Start with a once-daily framework

FDA is requesting that drug application holders remove information regarding the risk of suicidal ideation and behavior (SI/B) from the labeling of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications that currently include such language

the prescribing information for the pill makes some stipulations about timing the dose around food, while the injection doesnt

Interestingly, this drug class, although primarily used for metabolic control, may also possess anti-inflammatory properties, prompting investigators to further explore this prospect

Here at Real Peptides, our work goes beyond simply synthesizing high-purity research compounds